Strs Ohio Buys 24,284 Shares of Gilead Sciences, Inc. $GILD

Strs Ohio increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.5% during the 3rd quarter, Holdings Channel reports. The fund owned 558,587 shares of the biopharmaceutical company’s stock after acquiring an additional 24,284 shares during the period. Strs Ohio’s holdings in Gilead Sciences were worth $62,003,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its position in shares of Gilead Sciences by 1.6% during the second quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after purchasing an additional 1,893,401 shares during the period. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after acquiring an additional 727,515 shares in the last quarter. Norges Bank acquired a new stake in shares of Gilead Sciences in the 2nd quarter worth about $2,150,268,000. Invesco Ltd. boosted its stake in Gilead Sciences by 33.5% during the 2nd quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after purchasing an additional 3,394,330 shares during the last quarter. Finally, Amundi raised its stake in shares of Gilead Sciences by 18.2% in the second quarter. Amundi now owns 10,467,411 shares of the biopharmaceutical company’s stock worth $1,167,221,000 after purchasing an additional 1,614,355 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Trending Headlines about Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: NEJM published full Phase 3 ASCENT‑04/KEYNOTE‑D19 results showing Trodelvy (sacituzumab govitecan) + Keytruda met the primary endpoint with a ~35% PFS improvement (HR 0.65), supporting the combo as a potential new first‑line standard in PD‑L1+ metastatic TNBC — a major commercial catalyst for Gilead’s oncology franchise. NEJM ASCENT-04 Results
• Positive Sentiment: Multiple outlets (PharmaLetter) summarized the NEJM publication and reinforced the significance of the clinical data for Trodelvy’s uptake and reimbursement discussions — amplifying the immediate market reaction. PharmaLetter Trodelvy-Keytruda NEJM Coverage
• Positive Sentiment: Rothschild & Co Redburn raised its price target to $159 and kept a “buy” rating — a bullish institutional signal that supports further upside and likely contributed to buying momentum. Rothschild & Co Redburn Price Target
• Positive Sentiment: Investor commentary highlighting margin expansion and stronger free cash flow as underappreciated drivers has supported fundamental buying beyond the clinical news. Seeking Alpha on Margins & Cash Flow
• Neutral Sentiment: Market write‑ups and a Zacks note pointed out that GILD outpaced the broader market today — useful for context but largely descriptive of price action rather than new fundamental change. Zacks: Why GILD Outpaced Market
• Neutral Sentiment: Valuation and technical pieces note recent share‑price strength and improved momentum — these can attract traders but don’t alter the clinical/commercial thesis. Yahoo Valuation Check
• Negative Sentiment: Director Jeffrey Bluestone sold 5,000 shares (~$617.5k at ~$123.50), reducing his stake by ~36% — an insider sale that can prompt short‑term investor concern about timing or confidence (though insiders sell for many non‑signal reasons). SEC Form 4 — Bluestone
• Negative Sentiment: RBC’s price target (~$103, sector perform) remains well below current levels — a conservative analyst view that could limit upside if other firms adopt similar stances. RBC Price Target Note

Analysts Set New Price Targets

Several brokerages recently issued reports on GILD. Scotiabank began coverage on Gilead Sciences in a report on Thursday, November 13th. They set a “sector outperform” rating and a $140.00 price target for the company. JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Truist Financial initiated coverage on shares of Gilead Sciences in a report on Monday, November 24th. They issued a “buy” rating and a $140.00 target price for the company. Citigroup upped their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Finally, HSBC lifted their target price on shares of Gilead Sciences from $110.00 to $133.00 and gave the stock a “hold” rating in a research report on Wednesday, December 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $133.52.

Insiders Place Their Bets

In other Gilead Sciences news, EVP Deborah H. Telman sold 53,646 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the sale, the executive vice president owned 43,676 shares in the company, valued at $5,365,596.60. This represents a 55.12% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $122.00, for a total value of $366,000.00. Following the completion of the transaction, the chief financial officer directly owned 153,503 shares of the company’s stock, valued at $18,727,366. The trade was a 1.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 141,757 shares of company stock worth $17,569,112 in the last three months. Insiders own 0.27% of the company’s stock.

Gilead Sciences Stock Up 1.6%

Shares of NASDAQ GILD opened at $131.14 on Friday. The company has a debt-to-equity ratio of 1.03, a current ratio of 1.45 and a quick ratio of 1.31. The stock has a market capitalization of $162.70 billion, a PE ratio of 20.33, a P/E/G ratio of 0.68 and a beta of 0.33. Gilead Sciences, Inc. has a one year low of $92.21 and a one year high of $133.10. The business’s fifty day moving average price is $123.76 and its 200-day moving average price is $118.46.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. The business had revenue of $7.77 billion for the quarter, compared to analysts’ expectations of $7.42 billion. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same period in the previous year, the business posted $2.02 EPS. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, December 30th. Investors of record on Monday, December 15th were issued a $0.79 dividend. The ex-dividend date of this dividend was Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.4%. Gilead Sciences’s dividend payout ratio (DPR) is 48.99%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.